CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 531.2	$ 600.3
Trade receivables, net	1,770.7	1,676.4
Inventories, net	942.5	883.0
Prepaid expenses and other current assets	452.6	343.4
Assets held for sale	1,156.9	15.9
Deferred tax assets, net	309.8	366.9
Total current assets	5,163.7	3,885.9
Property, plant and equipment, net	1,319.6	1,234.2
Intangible assets, net	11,751.4	12,848.2
Goodwill	9,436.3	9,752.1
Deferred tax assets, net	18.3	54.9
Other long-term assets, net	206.3	195.5
Total assets	27,895.6	27,970.8
Current liabilities:
Accounts payable	327.7	327.0
Accrued and other current liabilities	1,774.9	1,800.2
Acquisition-related contingent consideration	88.9	114.5
Current portion of long-term debt	266.7	204.8
Liability held for sale	27.1	0
Deferred tax liabilities, net	11.0	66.0
Total current liabilities	2,496.3	2,512.5
Acquisition-related contingent consideration	238.1	241.3
Long-term debt	17,058.8	17,162.9
Pension and other benefit liabilities	165.5	172.0
Liabilities for uncertain tax positions	115.8	169.1
Deferred tax liabilities, net	2,238.8	2,319.2
Other long-term liabilities	215.0	160.5
Total liabilities	22,528.3	22,737.5
Commitments and contingencies (note 17)
Equity
Common shares, no par value, unlimited shares authorized, 333,777,181 and 333,036,637 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	8,325.9	8,301.2
Additional paid-in capital	212.2	228.8
Accumulated deficit	(3,175.3)	(3,278.5)
Accumulated other comprehensive loss	(104.7)	(132.8)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,258.1	5,118.7
Noncontrolling interest	109.2	114.6
Total equity	5,367.3	5,233.3
Total liabilities and equity	$ 27,895.6	$ 27,970.8